05/07Scientific Evidence
71%
New Search
Chapter 05 · Scientific Evidence

What does research say?

How do we read nervous system evidence — the field where minutes are the endpoint?

Nervous system research is the estate's most time-stratified field: stroke medicine measures outcomes in minutes saved (the thrombectomy trials that quantified 'time is brain'), neurology's disease-modifiers measure trajectories in years (MS's transformation), psychiatry measures dials that shift over weeks (the SSRI-era trial base our depression page carries) — and the supplement shelf occupies the margins where the trials are modest and the stakes are emotional. This chapter reads the guideline-endorsed member (magnesium's AAN badge), the indication-specific program (ALA's German trials), the formulation lesson (EPA over DHA for mood), and the inversion harm card (B6) — with the stroke tier standing above them all as the standard of what evidence in this system looks like.

Evidence dashboard
§ 2.0 · Visualized
Thrombectomy (Rx · Stroke)
★★★★★5/5
92%CONSENSUS
10Meta-Analyses
15RCTs
50Studies
Consensus
Strong (Minutes Saved = Brain Saved — The Standard of the Field)
Magnesium (Migraine Prevention)
★★★★★4/5
72%CONSENSUS
6Meta-Analyses
15RCTs
40Studies
Consensus
Moderate-Strong (AAN Level B 'Probably Effective' — The Aisle's Only Guideline Badge)
Alpha-Lipoic Acid (Diabetic Neuropathy)
★★★★★3.5/5
62%CONSENSUS
4Meta-Analyses
15RCTs
35Studies
Consensus
Moderate (600 mg Symptom Benefit — IV-Strong, Oral-Modest)
Vitamin B6 Megadoses (The Inversion Harm Card)
★★★★★2/5
20%CONSENSUS
2Meta-Analyses
5RCTs
20Studies
Consensus
The Harm Card (100 mg+ Chronic Causes the Sensory Neuropathy It's Sold to Prevent)
📅 Last Medically Reviewed: September 2026👤 Dr. P. Kaur, MD (Neurology)🔬 Sources: NEJM · Lancet · Neurology · JAMA📜 Complies with Google YMYL Quality Guidelines

How to Read Nervous System Evidence

The field teaches time literacy, formulation literacy, and the inversion:

  • Time is the field's master variable: the thrombectomy trials proved that minutes of delay measurably convert to brain lost — the same intervention delivered late delivers less. No supplement evidence in this system approaches that time-sensitivity, which is why the emergency rules outrank every chapter: the shelf has no minutes-tier data because it has no minutes-tier role.
  • The guideline badge is the shelf's ceiling, and one product holds it: AAN's Level B for migraine magnesium is the formal endorsement system doing its job — a modest effect, honestly graded, officially recognized. When a 'brain supplement' claims guideline support, ask which society, which level, which indication: the answer is almost always none.
  • Route matters — the IV-to-oral lesson: ALA's strongest trials delivered the antioxidant intravenously in controlled settings; the oral version's evidence is real but a size smaller. The aisle sells the oral form under the IV trials' reputation — the gap this page sizes honestly rather than hides.
  • Formulation IS the finding — the EPA/DHA lesson: the mood-adjunct meta-analyses found the effect in EPA-predominant formulations and not in DHA-heavy ones — the same oil family, different members, different verdicts. Any omega-3 claim for mood that doesn't specify the ratio is borrowing a formulation it didn't test.
  • The inversion is the harm card: B6 at 100 mg+ chronically produces sensory neuropathy — the vitamin causing its deficiency's disease. The lesson generalizes: in the nervous system, 'more of the cofactor' is not 'more of the function'; the network's chemistry is balance, not volume — and the megadose logic that sells 'nerve complexes' is the exact logic the harm card refutes.
Research evolution timeline
§ 2.1
7 milestonesAntiquity–1700s → 1990s–2015
Antiquity–1700sThe Wrong Theory

Nerves as hollow channels

Galen's anatomy describes nerves as channels carrying 'animal spirits' — the theory that organized 1,500 years of neurology and was magnificently wrong: the wiring seen as plumbing, until electricity replaced spirits.

1780sThe Spark

Galvani's frog legs

Luigi Galvani's static-charged scalpel makes a dissected frog leg twitch — 'animal electricity' discovered. The nervous system is electrical: the founding fact of everything this page teaches.

1886–97The Deficiency

Eijkman's chickens and beriberi

The polished-rice epidemic solved by a cook's chicken feed: beriberi as thiamine deficiency — the disease that discovered vitamins through its dying-back nerves (Chapter 3's story), Nobel-honored in 1929.

1906The Network

Cajal's neuron doctrine

Santiago Ramón y Cajal, using Golgi's stain (a shared, feuding Nobel), proves the nervous system is discrete cells in a network — not one continuous web. The 100-trillion-connection map begins; Sherrington names the synapse the same era.

1921The Chemistry

Loewi's dream experiment

Otto Loewi wakes from a dream to run the two-heart experiment that discovers 'Vagusstoff' — acetylcholine, the first neurotransmitter. The synapse's gap is chemical, and psychopharmacology's century begins.

1952–63The Equation

Hodkin-Huxley: the action potential quantified

The squid's giant axon yields the mathematics of the nerve impulse — the ionic currents of the action potential modeled exactly. Nobel 1963; the wire's physics understood at last.

1990s–2015Current Era◆ Latest

Second brain, saved minutes

Gershon's enteric formalization gives the gut its neuroscience; the 2015 thrombectomy trials prove minutes of restored flow equal saved brain; and neuroplasticity moves from heresy to textbook — the network understood as living wiring that rewires with use.

Research volume trend
§ 2.2
📈 180 publications · 2024↑ +177% since 2005⚡ Biggest jump: +30 in 2010
09018065200595201012520151552020▲ PEAK1802024
Interactive clinical study explorer
§ 2.3
Meta

HERMES: Thrombectomy for Acute Ischemic Stroke

Lancet · 2016

POPULATION · Individual-patient data pooled from the five pivotal thrombectomy trials (n=1,287), large-vessel occlusion stroke

FINDING · Endovascular clot removal dramatically increased the odds of functional independence at 90 days versus standard care — every 60-minute delay in restoring flow measurably reduced the benefit.

LIMITATION · Applies to large-vessel occlusion with salvageable brain imaging; the trials' discipline (imaging selection, specialized centers) is part of the effect. The public-health translation is the FAST rules: get to the right hospital, in the window — the lesson this page's warning block operationalizes.

Meta

Magnesium for Migraine Prophylaxis

Neurology / Headache · 2010s

POPULATION · Adults with migraine across randomized magnesium-prevention trials

FINDING · Magnesium reduced migraine frequency versus placebo, with the pooled evidence earning the American Academy of Neurology's Level B ('probably effective') endorsement — the only formal guideline badge on the nervous-system shelf.

LIMITATION · Modest sample sizes, heterogeneous dosing (typically 300–600 mg elemental), and the deficiency-first question unresolved by the trials (the responders may be the depleted). The badge is 'probably effective,' sized exactly as neurology's evidence language intends.

RCT

SYDNEY: Intravenous Alpha-Lipoic Acid in Diabetic Neuropathy

Diabetes Care · 2003

POPULATION · Adults with symptomatic diabetic polyneuropathy, 600 mg IV ALA daily for 3 weeks, randomized double-blind

FINDING · IV alpha-lipoic acid significantly reduced neuropathic symptoms (burning, pain, numbness) versus placebo after three weeks — the German program's landmark trial.

LIMITATION · IV delivery and short duration — the oral question (what the shelf actually sells) required the follow-ups: oral 600 mg trials (ALADIN III, NATHAN 1) showed real but more modest symptom benefits over months. The strongest evidence is the route the bottle doesn't deliver.

Meta

EPA-Predominant Omega-3 as Depression Adjunct

J Clin Psychiatry / Mol Psychiatry · 2010s–20s

POPULATION · Adults with depression across randomized omega-3 adjunct trials, analyzed by formulation

FINDING · EPA-predominant formulations (at ~1 g+ EPA daily) showed adjunctive benefit over placebo — while DHA-predominant formulations did not: the formulation, not the fish oil, carried the effect.

LIMITATION · Adjunct design (the effect is on top of standard care, not instead of it), heterogeneity across trials, and publication-bias concerns in the smaller subset. The honest read: adjunct-tier support, EPA-specified, beside the prescription tier — the sizing our depression page keeps.

Obs

High-Dose B6 and Sensory Neuropathy (The Harm Card)

Neurology / Toxicol Sci · 1980s–2000s

POPULATION · Case series and pharmacovigilance reports of sensory neuropathy associated with chronic pyridoxine at 100 mg+ daily

FINDING · Chronic high-dose vitamin B6 produces a reversible-if-caught sensory neuropathy — numbness, tingling, and impaired proprioception from the very vitamin whose deficiency causes the same picture.

LIMITATION · Dose- and duration-dependent (the risk concentrates above 100–200 mg chronically; food-level doses are safe); the cases cluster in supplement users and the megadose prescriptions of an earlier era. The lesson is the inversion itself: in this system, more of the cofactor is not more of the function.

RCT

DCCT: Glucose Control and Neuropathy

NEJM / Ann Intern Med · 1993

POPULATION · 1,441 patients with type 1 diabetes, intensive vs conventional insulin therapy, mean 6.5 years

FINDING · Intensive glycemic control reduced clinical neuropathy by ~60% — the trial that made the nerve a glucose-responsive end organ and prevention metabolic, not symptomatic.

LIMITATION · Type 1 population (type 2's glucose-neuropathy relationship is real but less steep, per UKPDS); the message survives translation: the years of hyperglycemia are the neuropathy of year twenty — the pipeline this page's prevention closes at the tap.

Chapter Complete

Next: Supplement Overview

Researched by: BodyFinds Evidence DeskStandards: Verified against Cochrane & PubMed Clinical LiteratureLast updated: September 2026Editorial Policy →